Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE Read more about Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects Read more about Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Read more about Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
A Multicenter Assessment of ALD403 in Chronic Migraine Read more about A Multicenter Assessment of ALD403 in Chronic Migraine
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Read more about "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Read more about Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Read more about Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Read more about A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) Read more about A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)